Details of the Drug Combination

General Information of Drug Combination (ID: DC8O5AX)

Drug Combination Name
Terameprocol Altretamine
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Terameprocol   DMC3P45 Altretamine   DMKLAYG
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HCT116
Zero Interaction Potency (ZIP) Score: 3.4
Bliss Independence Score: 8.34
Loewe Additivity Score: 4.06
LHighest Single Agent (HSA) Score: 2.77

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of Altretamine
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Approved [3]
Altretamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DC10R5C U251 Investigative [5]
Clear cell renal cell carcinoma DCVPFDW TK-10 Investigative [5]
Glioma DCGZ6PC SF-295 Investigative [5]
Plasma cell myeloma DC3GD3Z RPMI-8226 Investigative [5]
Colon adenocarcinoma DCMGCIZ COLO 205 Investigative [6]
Colon carcinoma DCPGIK7 KM12 Investigative [6]
Invasive ductal carcinoma DCSCSH4 HS 578T Investigative [6]
Adenocarcinoma DC310HB DU-145 Investigative [1]
Adenocarcinoma DC4DR58 OVCAR3 Investigative [1]
Adenocarcinoma DCBBWR5 A549 Investigative [1]
Melanoma DCJ7WYC UACC-257 Investigative [1]
Melanoma DCRWVOO MALME-3M Investigative [1]
Minimally invasive lung adenocarcinoma DCXJV1N NCI-H322M Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7112).
4 Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26.
5 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.